COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors (RIFTOS MKI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02303444
Recruitment Status : Completed
First Posted : December 1, 2014
Last Update Posted : August 12, 2020
Sponsor:
Information provided by (Responsible Party):
Bayer

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of the study is to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.

Condition or disease Intervention/treatment
Thyroid Neoplasms Drug: Sorafenib (Nexavar, BAY43-9006) Drug: Other Multikinase inhibitors

Detailed Description:
The primary objective of this study is to compare time to symptomatic progression (TTSP) from study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry with that of asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 667 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors
Actual Study Start Date : April 8, 2015
Actual Primary Completion Date : June 10, 2020
Actual Study Completion Date : July 24, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
MKI patients
Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
 Drug: Sorafenib (Nexavar, BAY43-9006)
Patients can get sorafenib at any time during study.

Drug: Other Multikinase inhibitors
Patients can get MKIs at any time during study.
non-MKI patients
Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
 Drug: Sorafenib (Nexavar, BAY43-9006)
Patients can get sorafenib at any time during study.

Drug: Other Multikinase inhibitors
Patients can get MKIs at any time during study.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to symptomatic progression (TTSP) from study entry [ Time Frame: Up to 6 years ]
    TTSP is defined as the time interval from the day of study entry to the date of first symptomatic progression. Patients who do not have a symptomatic progression at the time of analysis will be censored at the date of their last evaluable assessment.


Secondary Outcome Measures :
  1. Overall survival (OS) from time of study entry [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of study entry to death due to any cause. Patients alive at the time of analysis will be censored at the last date known to be alive.

  2. Progression free survival (PFS) from time of study entry [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of study entry to date of first progression or death due to any cause, whichever comes first. The actual date of tumor assessments will be used for this calculation. Patients without a progression or death will be censored at their last evaluable date of tumor evaluation.

  3. OS from time of being diagnosed as radioactive iodine (RAI) refractory [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of being diagnosed as RAI refractory to death due to any cause. Patients alive at the time of analysis will be censored at the last date known to be alive.

  4. Post-progression survival (PPS) from time of symptomatic progression [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of symptomatic progression to death due to any cause. Patients without symptomatic progression will be excluded from analysis and patients who are alive at the time of analysis will be censored at the last date when they were known to be alive.

  5. OS from initiation of the first Multikinase Inhibitor (MKI) [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of start of the first MKI to death due to any cause. Patients alive at the time of analysis will be censored at the last date when they were known to be alive.

  6. PFS from initiation of first MKI [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of start of first MKI to date of first progression or death due to any cause, whichever comes first. The actual date of tumor assessments will be used for this calculation. Patients without a progression or death will be censored at their last evaluable date of tumor evaluation.

  7. OS from initiation of any systemic treatment regimen [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of start of any systemic treatment regimen to death due to any cause. Patients alive at the time of analysis will be censored at the last date known to be alive.

  8. PFS from initiation of any systemic treatment regimen [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of start of any systemic treatment regimen to date of first progression or death due to any cause, whichever comes first. Patients without a progression or death will be censored at their last evaluable date of tumor evaluation.

  9. Duration of each systemic treatment regimen [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of start of a treatment to the date of permanent discontinuation of a treatment (regardless of the reason for discontinuation including death). It includes interruption or drug holiday.

  10. Response assessment to each systemic treatment regimen according to the categories "Complete Response", "Partial Response", "Stable Disease", "Clinical Progression", "Radiological Progression", and "Not evaluable at this visit" [ Time Frame: Up to 6 years ]
    In case of "Clinical Progression" the CRF will ask for the presence of specific symptoms.

  11. OS from initiation of sorafenib [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of start of sorafenib to death due to any cause. Patients alive at the time of analysis will be censored at the last date known to be alive.

  12. PFS from initiation of sorafenib [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of start of sorafenib to date of first progression or death due to any cause, whichever comes first. Patients without a progression or death will be censored at their last evaluable date of tumor evaluation.

  13. Daily dose of sorafenib per patient throughout the treatment period [ Time Frame: Up to 6 years ]
  14. Number of adverse events during treatment with sorafenib [ Time Frame: Up to 6 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Any setting that provides treatment for progressive asymptomatic RAI refractory DTC
Criteria

Inclusion Criteria:

  • Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and poorly differentiated carcinoma)
  • DTC refractory to RAI
  • Radiological progression and preferably according to RECIST 1.1
  • No symptoms due to DTC
  • >/=1cm diameter of lesion confirmed by radiological exam
  • Life expectancy of at least 6 months

Exclusion Criteria:

  • Plan to be treated according to a clinical trial protocol for intervention including a locoregional therapy or systemic therapy
  • Previous treatment with MKIs for advanced disease
  • Hospice patients
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02303444


Locations
Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, California
Los Angeles, California, United States
Torrance, California, United States
United States, Colorado
Aurora, Colorado, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Plantation, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Illinois
Chicago, Illinois, United States
United States, Louisiana
New Orleans, Louisiana, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
United States, New York
Bronx, New York, United States
United States, North Carolina
Durham, North Carolina, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Texas
Dallas, Texas, United States
Algeria
Multiple Locations, Algeria
Argentina
Multiple Locations, Argentina
Brazil
Multiple Locations, Brazil
Egypt
Multiple Locations, Egypt
France
Multiple Locations, France
Germany
Multiple Locations, Germany
Greece
Multiple Locations, Greece
India
Multiple Locations, India
Japan
Multiple Locations, Japan
Lebanon
Multiple Locations, Lebanon
Mexico
Multiple Locations, Mexico
Netherlands
Multiple Locations, Netherlands
Philippines
Multiple Locations, Philippines
Russian Federation
Multiple Locations, Russian Federation
Saudi Arabia
Multiple Locations, Saudi Arabia
Spain
Multiple Locations, Spain
Taiwan
Multiple Locations, Taiwan
Turkey
Multiple Locations, Turkey
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02303444    
Other Study ID Numbers: 17852
NX1401 ( Other Identifier: Company internal )
First Posted: December 1, 2014    Key Record Dates
Last Update Posted: August 12, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Progressive radioactive iodine refractory differentiated thyroid carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
 Head and Neck Neoplasms
Sorafenib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action